In the last trading session, 1.28 million shares of the Olema Pharmaceuticals Inc (NASDAQ:OLMA) were traded, and its beta was 2.07. Most recently the company’s share price was $5.16, and it changed around -$0.53 or -9.31% from the last close, which brings the market valuation of the company to $352.60M. OLMA currently trades at a discount to its 52-week high of $16.77, offering almost -225.0% off that amount. The share price’s 52-week low was $4.60, which indicates that the current value has risen by an impressive 10.85% since then. We note from Olema Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 1.26 million shares, with the 3-month average coming to 1.10 million.
Olema Pharmaceuticals Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 0 recommended OLMA as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. Olema Pharmaceuticals Inc is expected to report earnings per share of 0.17 for the current quarter.
Olema Pharmaceuticals Inc (NASDAQ:OLMA) trade information
Instantly OLMA has showed a red trend with a performance of -9.31% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 6.70 on recent trading dayincreased the stock’s daily price by 22.99%. The company’s shares are currently down -11.49% year-to-date, but still down -13.42% over the last five days. On the other hand, Olema Pharmaceuticals Inc (NASDAQ:OLMA) is -10.26% down in the 30-day period. We can see from the shorts that 10.87 million shares have been sold at a short interest cover period of 8.38 day(s).
The consensus price target as assigned by Wall Street analysts is $27, which translates to bulls needing to increase their stock price by 80.89% from its current value. Analyst projections state that OLMA is forecast to be at a low of $27 and a high of $27.
Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -105.28%. Olema Pharmaceuticals Inc earnings are expected to increase by -7.49% in 2025, but the outlook is negative -13.34% per year for the next five years.
OLMA Dividends
Olema Pharmaceuticals Inc’s next quarterly earnings report is expected to be released in March.
Olema Pharmaceuticals Inc (NASDAQ:OLMA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 3.21% of Olema Pharmaceuticals Inc shares, and 89.36% of them are in the hands of institutional investors. The stock currently has a share float of 92.32%. Olema Pharmaceuticals Inc stock is held by 202.0 institutions, with BVF INC/IL being the largest institutional investor. By 2024-06-30, it held 16.2322% of the shares, which is about 9.14 million shares worth $98.85 million.
PARADIGM BIOCAPITAL ADVISORS LP, with 14.0428% or 7.9 million shares worth $85.52 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
